![]() ![]() 229920002892 amber Polymers 0.000 claims abstract description 109.108020004705 Codon Proteins 0.000 claims abstract description 150.241000203407 Methanocaldococcus jannaschii Species 0.000 claims abstract description 197.150000001413 amino acids Chemical class 0.000 claims abstract description 431.238000004519 manufacturing process Methods 0.000 title description 13.102000003960 Ligases Human genes 0.000 title claims description 279.229920001949 Transfer RNA Polymers 0.000 title claims abstract description 392.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to US28503001P priority Critical Priority to US285030P priority Priority to US35551402P priority Priority to US355514P priority Application filed by University of California, Scripps Research Institute filed Critical University of California Application granted granted Critical Publication of ES2464532T3 publication Critical patent/ES2464532T3/en Anticipated expiration legal-status Critical Status Expired - Lifetime legal-status Critical Current Links Original Assignee University of California Scripps Research Institute Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) ![]() Meggers Ryan Aaron Mehl Miro Pastrnak Stephen William Santoro Zhiwen Zhang Current Assignee (The listed assignees may be inaccurate. Inventor Peter Schultz Lei Wang John Christopher Anderson Jason W. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Expired - Lifetime Application number ES09006800.8T Other languages Spanish ( es) ENSAYO DE COMPARACION Y CONTRASTE PDFDifferent pharmacological agents have been tested, but the use of iso-osmolar or hypo-osmolar contrast agents along with continuous hydration before, during, and after the intervention are the only methods that have currently achieved adequate nephroprotection.Methods and compositions for the production of orthogonal pairs of tRNA-aminoacyl-tRNA synthetaseĭownload PDF Info Publication number ES2464532T3 ES2464532T3 ES09006800.8T ES09006800T ES2464532T3 ES 2464532 T3 ES2464532 T3 ES 2464532T3 ES 09006800 T ES09006800 T ES 09006800T ES 2464532 T3 ES2464532 T3 ES 2464532T3 Authority ES Spain Prior art keywords trna amino acid synthetase unnatural amino amino acids Prior art date Legal status (The legal status is an assumption and is not a legal conclusion. As there is no specific treatment available for this condition, emphasis should be placed on prevention. It is the third leading cause of in-hospital acute kidney injuries, and it leads to an increase in morbidity and mortality of the population. Contrast-induced nephropathy is defined as an absolute (≥ 0.5 mg/dL) or relative increase (≥ 25%) of the serum creatinine within 24-72 hours post-exposure to the contrast media. It is estimated that the incidence is about 0-5% among the population with normal renal function however it can reach 12-27% among people with altered baseline renal function. The use of contrast media in the diagnostic and therapeutic medical arsenal can cause adverse effects, such as renal toxicity and acute kidney injury, known as contrast-induced nephropathy. Se han probado distintos agentes farmacológicos, sin embargo, hoy en día los únicos métodos que han logrado asegurar adecuada nefroprotección son el uso de agentes de contraste isoosmolares o de baja osmolaridad junto con hidratación continua del paciente antes, durante y después de la intervención. Por tanto, el énfasis se realiza en la prevención. No se dispone de un tratamiento específico para esta entidad. Es la tercera causa de injuria renal aguda intrahospitalaria y conlleva un aumento en la morbimortalidad de la población. La nefropatía inducida por contraste se define como un aumento absoluto (≥ 0,5 mg/dl) o relativo (≥ 25%) de la creatinina sérica en 24-72 h postexposición al medio de contraste. Se estima que en la población con función renal normal la incidencia es del 0-5% sin embargo, en personas con alteración de la función renal basal puede llegar a un 12-27%. El uso de medios de contraste dentro del arsenal diagnóstico y terapéutico médico puede ocasionar efectos adversos como toxicidad renal e injuria renal aguda, conocida como nefropatía inducida por contraste. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |